EPO and hemochromatosis type 1: While identification and pharmacological targeting of these factors may provide novel clinical therapies for the treatment of hemochromatosis or anemia of chronic disease (ACD), the pharmacological HIF inducers which are currently in clinical trials may exert suppressive effects on hepcidin as a consequence of the induction of erythropoiesis by increasing erythropoietin production and would therefore not be illogical treatments for ACD.